The Proposed Pan-Canadian Guidance for Newborn Screening: What We Heard

Date: Tuesday, March 4, 1:00 p.m. to 2:00 p.m. ET
Location: Free online event

In support of the Government of Canada’s National Strategy for Drugs for Rare Diseases, Canada’s Drug Agency established a Newborn Screening Advisory Panel to develop pan-Canadian guidance for decision-makers about newborn screening. Join Dr. Hilary Vallance and Whitney Ayoub-Goulstone, cochairs of our Newborn Screening Advisory Panel, as they discuss highlights from the input received on a discussion paper outlining the proposed guidance for newborn screening across Canada.

In July 2024, an information session was held to share the Newborn Screening Advisory Panel’s scope of work related to newborn screening. The advisory panel prepared a discussion paper to contribute to the dialogue around this work, and a public call was launched, inviting interested parties to provide written input via an online questionnaire. Birthing providers who are from or work with underrepresented and underserved populations, and persons who are First Nations, Métis, or Inuit, also provided input through focus group discussions and key informant interviews.

The upcoming session will provide interested parties with an overview of the input received through these engagement activities and how it informed the advisory panel’s recommendations (final recommendations to be published in the spring of 2025). Additional information about the advisory panel and its work is available on the CDA-AMC website.

Register now